KMC Gastroenterology are excited to share that the U.S. Food and Drug Administration has approved ORBERA™ to assist adult patients suffering from obesity – with a bodymass index (BMI) of 30 to 40 – in losing and maintaining weight. ORBERA™ is a safe and effective weight loss solution with 20 years of global experience and real world results. More than 220,000 ORBERA™ balloons distributed worldwide in over 80 countries. KMC Gastroenterology is one of the first in the country to offer this new tool in helping people achieve their weight loss goals. “This is just one of many procedures we offer at KMC to stay at the forefront of GI services for Kansas residents,” said Shekhar Challa, MD, president at Kansas Medical Clinic, PA.
The ORBERA™ balloon is part of the ORBERA™ Managed Weight Loss System, a comprehensive, non-surgical two-part program that includes a balloon filling space in a patient’s stomach to reinforce proper portion control. Data on ORBERA™ collected in the U.S. clinical trial has shown that the average person lost 3.1 times the weight as compared with diet and exercise alone within six months.
KMC Gastroenterology recognizes that obesity is a chronic disease and we are pleased to be able to offer new, minimally invasive solutions, like ORBERA™, to help transform the lives of patients before their disease progresses and requiresmore invasive treatment.
For additional information regarding ORBERA™ at KMC Gastroenterology, please visit KMCPA.com/go/orbera. To schedule an interview with Dr. Shekhar Challa, please contact Sarah Legg, Marketing Director KMCPA, at 913-451-9351 or email@example.com.